01Connect Biopharma (CNTB) will report Q3 2026 earnings on November 11 after market close, with analysts expecting a loss of $0.26 per share versus breakeven last year.
02Revenue is projected at $4.1M, representing growth from the prior year quarter, though the company remains unprofitable.
03The stock trades at $0.70 with a market capitalization of $136.4M and has shown losses in recent quarters ranging from $0.27 to $0.34 per share.
04Recent earnings surprises have been mixed, with Q2 beating estimates by 12.9% but Q1 missing by 21.4%, suggesting volatile performance relative to forecasts.
Earnings Results
Connect Biopharma Holdings Limited (NASDAQ:CNTB) is scheduled to report its Q3 earnings results on November 11, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.26, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at $4.1M, up from a year ago.
Company Overview
The stock currently trades at $0.70 with a market capitalization of $136.4M.
Ahead of Connect Biopharma Holdings Limited's earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Connect Biopharma Holdings Limited should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Connect Biopharma Holdings Limited Earnings History